Compare · NVO vs TYRA
NVO vs TYRA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Tyra Biosciences Inc. (TYRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TYRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 121.1x TYRA ($1.58B).
- Over the past year, NVO is down 44.4% and TYRA is up 157.1% - TYRA leads by 201.5 points.
- TYRA has been more active in the news (11 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 21 for TYRA).
- Company
- Novo Nordisk A/S
- Tyra Biosciences Inc.
- Price
- $41.94-2.34%
- $26.56-0.30%
- Market cap
- $191.82B
- $1.58B
- 1M return
- -8.33%
- -19.81%
- 1Y return
- -44.38%
- +157.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 11
- Recent ratings
- 25
- 21
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Tyra Biosciences Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest TYRA
- SEC Form 8-K filed by Tyra Biosciences Inc.
- SEC Form 4 filed by Director Ra Capital Management, L.P.
- SEC Form 4 filed by Director Simson Jake
- SEC Form 4 filed by Director Moran Susan
- SEC Form 4 filed by Director Verjee Rehan
- SEC Form 4 filed by Director Gulfo Adele M.
- SEC Form 4 filed by Director Rothenberg Stephen Michael
- SEC Form 4 filed by Director More Robert J
- SEC Form 144 filed by Tyra Biosciences Inc.
- TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY